Our pharmaceutical trade growth restored to pre-crisis levels

Although pharmaceutical market demand recovery at home and abroad, but in uncertain, unstable economic factors significantly increased at the same time, China's pharmaceutical trade situation more complex.

According to Chinese medicines and health products import and export Chamber of Commerce (hereinafter referred to as "Medicare Chamber") statistical data showed that as of the third quarter of this year, China's pharmaceutical import and export growth has been largely restored to pre-crisis levels, the amount of monthly import and export from 40 million to 50 million interval to steadily billion-60 million range. From the data and the corresponding index, year medicine total imports and exports is expected to be slightly beyond 2009; of these, exports and imports are will achieve new breakthroughs.

"If you do not have a variety of factors, this year the pharmaceutical trade situation is expected to recover to the financial crisis nearly $ 60 billion total imports and exports. But this year the price of raw materials and the exchange rate soaring two prominent factors, fourth-quarter increase in turnover of pharmaceutical export will be slowed, conservative estimates annual increase of 20%. "Medical insurance Association Secretary-General Cui bin to the pharmaceutical economic newspaper reporters, pharmaceutical trade still in shock and fluctuations in the front row.

The first three quarters of the movements of the "V"

According to the medical insurance Association, the latest statistics, 2010-1 ~ in September, my Medicare products import and export amount accumulated $ 439.6 billion, an increase of 26.7%, of which exports 290.7 billion, an increase of 27.6%; import 148.9 billion, an increase of 24.8%; exports compared relatively substantial increase, the trade surplus grew by 31% year-on-year, $ 141.9 million.

"It can be said that at present the basic import and export growth has recovered to the level before the financial crisis, the future can maintain its steady growth has yet to be tested. "Cui bin pointed out that, during the third quarter of this year, China's pharmaceutical products monthly fluctuations and export chain, the overall trend is obvious" V "-type, three-ring than respectively-0.42%,-3.98% and 6.46%, September, and export 53.8 million for this year was the highest monthly imports growth, 19.7 million ring than 13.6 percent.

Reflected in the category, Western medicine, Chinese medicine, and medical device product differentiation and export performance. Western medicine class while rendering and export booming trend, but the raw material price increases resulting in increased cost and other factors, its price downturn have changed state short-term; medical device class and export growth, but commodity exports increased risk; and the quality of Chinese class quantity price increase, the prices of Chinese Qi move rapidly, but also because herbal raw material price rally or expose the price too high of a risk reduction.

In Western medicine three classified goods, raw materials and West Medicine exports prices Qi sheng, biochemical drug is an atrophy of exports, but the price factor of strong, driven by exports as a whole is still solid growth. According to Medicare's data show that the first three quarters of this year, pharmaceutical products and export amounted to 269 million, an increase of 27.2%, the proportion of the total amount of the total industry 61.2%; exports 177.5 billion, an increase of 30%, import 91.5 billion, an increase of 22.1%.

Note that bulk medicine exports overall downward trend, an atrophy of enterprises in export earnings. In respect of exports of the top 20 large variety with class view, 19 products export volume growth, more than half of the species exceeds 30%, other amino acids exports increase over 64.6%. But from the export price, 10 products export price decline, vitamin C and other macrolide products decrease 26.3 13.2 percent. Cui Yanbin believes that Western medicine exports volume price fall shows that many products in the market for maintenance and growth are achieved at the expense of price, this one comes from the pressure of international competition, but more of a domestic production capacity surplus, low price competition between enterprises, in the short term there is a large difference.

As accounting for more than one third of pharmaceutical trade share of medical products, the third quarter of 2010 and export has reached 152.3 billion, an increase of 26.8%; exports 100 billion, an increase of 25%, import 52.5 billion, an increase of 30.4%; trade surplus 47.3 billion, an increase of 19.4%. In General, medical equipment trade continued large surpluses, while the domestic market demand is steadily increasing.

The medical device class commodity exports, health rehabilitation supplies, dressing and hospital diagnosis and treatment equipment will continue to maintain rapid growth, exports up 30.2% respectively, 27.1% and 25.9% cumulative 24.8 million, 41.8 billion and 40.9 billion. As exports ranking of medical products, medical dressings is this year's export volume price drop trend, export volume increased 53.2%, average price declined 17%.

"Considering the year cotton and other raw materials prices and labour costs rose significantly by the dressings, our product quality control limits run or situation will tend to be lower than the lower bound. "Cui said.

In addition, the first three quarters of this year, the traditional Chinese medicine products import and export of foreign trade growth, amounting to $ 18.4 billion, an increase of 20.1%, of which exports 13.5 billion, an increase of 20.5%. Chinese exports continued to plant extracts and herbal and other raw materials of products accounted for more than most, two together accounted for the total export value of traditional Chinese medicine 81%. As traditional Chinese medicine class of proprietary products with high added value of exports only 10.5%, limited market demand.

Primary secondary factors continuous fermentation

"This year, the most prominent of the two factors is the exchange rate and raw material prices. "Interview, Cui Yanbin has repeatedly told reporters that the two major factors on pharmaceutical foreign trade this year, the enormous influence.

"For a long time, China's pharmaceutical foreign trade enterprises to exchange rate differences on a larger profit margin generally smaller, the appreciation of the RMB will no doubt continue to bring greater losses. "Cui Yanbin

Pointed out that the current pharmaceutical trade still does not change the general way to the dollar, so exchange rate surges on phagocytosis of pharmaceutical trade enterprises profit the most.

But with the further intensification of exchange rates, the fourth quarter of this year, Europe, major economies in the appreciation of the Renminbi issues will continue to exert pressure on China, and sponsor for China manufacturing pharmaceutical products trade conflicts. Medical insurance Association believes that, as the emerging countries in low-end pharmaceutical products and our competition is increasingly fierce, and emerging market countries trade friction is likely to increase the number of cases.

In addition, raw material prices are also affecting pharmaceutical foreign trade this year's outstanding problems.

"Raw materials, water, electricity, coal, oil prices generally rise not only to the pharmaceutical industry, but all industries are faced with production costs. "Cui Yanbin further noted that in addition to the sharp rise in the exchange rate and raw material prices of main effects, environmental investment, taxation, intellectual property costs, product upgrading and the industry as an element of increased costs, as well as national trade protectionism further rise, will become the international competitiveness of China's foreign trade products of secondary factors. (Source: International Pharmaceutical Excipients network)